CLPT vs. DCTH, DRTS, QIPT, ARAY, CVRX, OBIO, PROF, TELA, KRMD, and BWAY
Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Delcath Systems (DCTH), Alpha Tau Medical (DRTS), Quipt Home Medical (QIPT), Accuray (ARAY), CVRx (CVRX), Orchestra BioMed (OBIO), Profound Medical (PROF), TELA Bio (TELA), KORU Medical Systems (KRMD), and BrainsWay (BWAY). These companies are all part of the "surgical & medical instruments" industry.
ClearPoint Neuro (NASDAQ:CLPT) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
ClearPoint Neuro has a net margin of -78.84% compared to Delcath Systems' net margin of -2,308.86%. ClearPoint Neuro's return on equity of -76.92% beat Delcath Systems' return on equity.
ClearPoint Neuro has higher revenue and earnings than Delcath Systems. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
ClearPoint Neuro has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Delcath Systems received 3 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 22.33% of users gave Delcath Systems an outperform vote.
ClearPoint Neuro currently has a consensus target price of $12.00, indicating a potential upside of 87.50%. Delcath Systems has a consensus target price of $20.20, indicating a potential upside of 190.23%. Given Delcath Systems' higher possible upside, analysts clearly believe Delcath Systems is more favorable than ClearPoint Neuro.
In the previous week, Delcath Systems had 11 more articles in the media than ClearPoint Neuro. MarketBeat recorded 18 mentions for Delcath Systems and 7 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.00 beat Delcath Systems' score of 0.49 indicating that ClearPoint Neuro is being referred to more favorably in the media.
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 17.9% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
ClearPoint Neuro beats Delcath Systems on 9 of the 17 factors compared between the two stocks.
Get ClearPoint Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearPoint Neuro Competitors List
Related Companies and Tools
